Company: CORT
Filing Date: 2025-10-14
Form Type: 8-K
Source: 0001193125-25-237834
Chunk: 0

Company: CORCEPT THERAPEUTICS INC
Filing Date: 2025-10-14
Form: 8-K
Item: Item 1.02
Chunk 0
---
Item 1.02.      Termination of a Material Definitive Agreement.  

On October 10, 2025, Corcept Therapeutics Incorporated (the “ Company”) delivered to Optime Care, Inc. (“ Optime”) a notice of termination of that certain Distribution Services Agreement, dated August 4, 2017, as amended and restated on April 1, 2024, by and between Optime and the Company (the “ Agreement”), effective as of January 8, 2026.

As previously disclosed, under the terms of the Agreement, Optime has acted as a specialty pharmacy distributor of Korlym®and the Company’s authorized generic mifepristone medication (the “ Medications”). Optime provided services related to pharmacy operations; patient intake, access and reimbursement; patient support; claims management and accounts receivable; and reporting (“ Pharmacy Services”). Effective April 1, 2024, the Company extended the Agreement with Optime through March 31, 2027, with automatic renewal for successive three-year terms. On June 17, 2025, the Company notified Optime that, pursuant to the Company’s rights under Section 18.5 of the Agreement, Optime would cease to be the exclusive provider of Pharmacy Services with respect to the Medications, effective September 15, 2025.

The Agreement was subject to customary termination provisions, including the right of Optime to terminate in the event of a material breach by the Company that the Company does not cure in a reasonable period of time after receiving written notice. The Agreement further provides that the Company has the right to terminate the Agreement for convenience at any time with90-daysadvance notice.

The description of the Agreement in this Current Report on Form8-K(“ Form 8-K”)does not purport to be complete and is subject to, and is qualified in its entirety by reference to the Agreement, which the Company initially filed as Exhibit 10.2 to its Quarterly Report on Form10-Qfor the three months ended March 31, 2024, filed with the SEC on May 1, 2024.